Dernières nouvelles pour Liberty Broadband (NASDAQ:LBRDK) Stock

Liberty Broadband

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

WIIM

HOUS

Anywhere Real Estate shares are trading higher. The company reported Q2 financial results.

Tesla Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) ambitious ventures beyond electric vehicles are capturing the attention of investors and analysts alike, as the company sets its sights on revolutionizing transportation and automation. A Tesla analyst says the electric vehicle giant could be <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46672257/tesla-worth-30-trillion-elon-musk-says-yes-but-investors-say-no">worth significantly more</a> in the future thanks to its goals in robotaxis, FSD and humanoid robots.
<ul class="wp-block-list">
<li>TSLA is slipping lower. <a href="https://www.benzinga.com/quote/TSLA" target="_blank" rel="noreferrer noopener">See the chart here.</a></li>
</ul>
The Tesla Analyst: RBC Capital analyst Tom Narayan maintained an Overweight rating on Tesla and raised the price target from $319 to $325.
Read Also: <a href="https://www.benzinga.com/markets/earnings/25/07/46587882/tesla-q2-earnings-highlights-revenue-and-earnings-fall-short-new-models-still-set-for-2025-2026">Tesla Q2 Earnings Highlights: Revenue And Earnings Fall Short; New Models Still Set For 2025–2026</a>
The Analyst Takeaways: Tesla's robotaxi launch in Texas was better than many investors and analysts feared, Narayan said in a new investor note.
"Should Tesla be successful on all of its goals, its valuation could far exceed even current levels," Narayan said.
Narayan highlighted that Tesla is looking to expand its robotaxi service to more cities, in addition to already expanding its initial robotaxi area in Austin, Texas. Robotaxis remains a key catalyst for Tesla for the future, according to the analyst.
"The goal is to reach half of the US population by year-end, although we expect this is a stretch target."
Tesla's full self-driving (FSD) is another key catalyst to the Tesla long-term bullish thesis, the analyst said. Narayan highlights that Tesla is seeing a 25% increase in adoption rates of FSD since the launch of FSD V.12 in North America.
Narayan said Tesla is also working on getting FSD approved in Europe and is hoping for an unblock to provide the service in China.
With the future launch of the Optimus Bot, a humanoid robot, Naryan factors in a global valuation for this segment in the latest price target. The previous price target only included a small estimate for the U.S. region.
"Humanoid robots could be significant."
Narayan highlighted Tesla's goal of having one million units of Optimus produced per year in less than five years. The analyst's valuation for humanoid robots assumes the use of Optimus exclusively for manufacturing jobs.
"The reality is should these be used for home/retail purposes, the potential upside could be far greater than any other Tesla business."
While there are positives for Tesla, the analyst noted that the end of federal tax credits could put pressure on the company's electric vehicle segment over the next several quarters.
To reach a new price target, Narayan values the car business at a 1.0x EV multiple and then applies various multiples to the other businesses, discounting the value accordingly.
Here is the base value assumption of the Tesla segments to reach a price target of $325:
<ul class="wp-block-list">
<li>Megapacks: $134.2 billion</li>
<li>Robotaxis: $649.2 billion</li>
<li>FSD: $185.6 billion</li>
<li>Humanoid Robots: $36.6 billion</li>
<li>Cars: $136.5 billion</li>
</ul>
Narayan said this could be a conservative valuation for Tesla. The analyst also provides an upside valuation for each segment, which sees Tesla reach a price target of $413. Here are the upside valuations of the segments:
<ul class="wp-block-list">
<li>Megapacks: $161.1 billion</li>
<li>Robotaxis: $876.3 billion</li>
<li>FSD: $206.8 billion</li>
<li>Humanoid Robots: $73.2 billion</li>
<li>Cars: $136.5 billion</li>
</ul>
Narayan said the Outperform rating is based on growing global EV demand and Tesla's ability to fund growth in other product areas.
TSLA Price Action: Tesla stock is down 1.5% to $320.83 on Tuesday versus a 52-week trading range of $182.00 to $488.54. Tesla stock is down 15.4% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/07/46620076/elon-musk-biopic-who-should-play-tesla-ceo-grok-picks-these-6-actors">Elon Musk Biopic: Who Should Play Tesla CEO? Grok Picks These 6 Actors</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Price Target

Reiteration

Analyst Ratings

Trading Ideas

TSLA

Tesla Valuation 'Could Far Exceed Current Levels': Analyst Sees 2 Segments Driving Most Upside (And It's Not Cars)

GBFH

GBank Financial Holdings shares are trading lower after the company reported mixed Q2 financial results.

Scotiabank analyst Konark Gupta maintains TFI International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TFII#TSX">TFII</a>) with a Sector Perform and raises the price target from C$140 to C$144.

News

TSX:TFII

Scotiabank Maintains Sector Perform on TFI International, Raises Price Target to C$144

Morgan Stanley analyst Erik Woodring maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Overweight and lowers the price target from $85 to $83.

Morgan Stanley Maintains Overweight on Western Digital, Lowers Price Target to $83

MBIN

Merchants Bancorp shares are trading lower after the company reported worse-than-expected Q2 EPS results. Also, Morgan Stanley and Raymond James lowered their respective price targets on the stock.

HC Wainwright &amp; Co. analyst Andrew Fein upgrades Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) from Neutral to Buy and raises the price target from $4 to $12.

Upgrades

FULC

HC Wainwright & Co. Upgrades Fulcrum Therapeutics to Buy, Raises Price Target to $12

Bernstein analyst William Pickering initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Market Perform rating and announces Price Target of $13.

Initiation

SRPT

Bernstein Initiates Coverage On Sarepta Therapeutics with Market Perform Rating, Announces Price Target of $13

Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) has outperformed the market over the past 10 years by 18.79% on an annualized basis producing an average annual return of 30.55%. Currently, Monolithic Power Systems has a market capitalization of $36.03 billion. 
Buying $1000 In MPWR: If an investor had bought $1000 of MPWR stock 10 years ago, it would be worth $14,201.70 today based on a price of $738.55 for MPWR at the time of writing.
<h3>Monolithic Power Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753803014_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPWR

$1000 Invested In Monolithic Power Systems 10 Years Ago Would Be Worth This Much Today

Rumors

Watching Wells Fargo & Company; Shares See Increase In Volume To The Downside, Hearing Popular Traders Newsletter Mentions They Sold The Stock

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and lowers the price target from $48 to $46.

EXEL

Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $46

Management

MJID

Majestic Ideal Holdings Appoints Jiang Lina As Chief Executive Officer Effective July 29, 2025

Morgan Stanley analyst Manan Gosalia maintains Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) with a Equal-Weight and lowers the price target from $40 to $34.

Morgan Stanley Maintains Equal-Weight on Merchants Bancorp, Lowers Price Target to $34

There could be further risk to Lululemon Athletica Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) estimates, given its continued product execution issues and sale section growth, according to Piper Sandler.
The Lululemon Athletica Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5935519f85b07a0001c0bc54/anna-andreeva">Analyst Anna Andreeva</a> maintained a Neutral rating, while reducing the price target from $270 to $200.
The <a>Lululemon Athletica</a> Thesis: The company has 57 instances of innovation and newness in color year to date, which is almost three times the levels last year, Andreeva said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The number of SKU&#8217;s on sale from the We Made Too Much tab started to pick up mid-June, the analyst wrote. The last three weeks of July ran in the 1,000+ SKU range, levels now slightly above last Holiday and vs.~600 SKU&#8217;s on average last July.
Lululemon offered a 25% discount on as many as 15 full-priced items in June, she added.
This over-investment is evident from new products moving quickly to the clearance racks, which helps explain the higher discounting being offered, Andreeva further stated.
Price Action: Shares of Lululemon Athleticahadrisen by 0.64% to $217.97 at the time of publication on Tuesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/07/46371957/netflixs-squid-game-reality-show-gets-season-2-date-4-56-million-prize-without-the-killing">Is Lululemon Headed For Its Nike Moment?</a></li>
</ul>
Image: Shutterstock

LULU

Lululemon Athletica Is 'Over-Investing In Innovation,' Analyst Cuts Price Target

Morgan Stanley analyst Joseph Moore maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Equal-Weight and raises the price target from $19 to $20.

AMKR

Morgan Stanley Maintains Equal-Weight on Amkor Tech, Raises Price Target to $20

Scotiabank analyst Himanshu Gupta maintains StorageVault Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SVI#TSX">SVI</a>) with a Sector Outperform and raises the price target from C$5 to C$5.5.

TSX:SVI

Scotiabank Maintains Sector Outperform on StorageVault Canada, Raises Price Target to C$5.5

Grupo Televisa shares are trading higher after UBS maintained a Neutral rating on the stock and raised its price target from $2.4 to $2.5

Morgan Stanley analyst James Faucette maintains Western Union (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WU#NYSE">WU</a>) with a Underweight and lowers the price target from $9 to $7.

Morgan Stanley Maintains Underweight on Western Union, Lowers Price Target to $7

PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) announced it has gained FDA approval for <a href="https://www.benzinga.com/quote/PTCT">SEPHIENCE on Monday</a>.
&#8220;We are excited to have reached this important milestone for those affected by PKU,&#8221; said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. &#8220;The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our experienced customer facing teams are ready to bring this therapy to children and adults with PKU in the United States as quickly as possible.&#8221;
PTC Therapeutics shares gained 11.7% to trade at $49.53 on Tuesday.
These analysts made changes to their price targets on PTC Therapeutics following the announcement.
<ul class="wp-block-list">
<li>UBS analyst Colin Bristow maintained PTC Therapeutics with a Buy and raised the price target from $71 to $80.</li>
<li>Cantor Fitzgerald analyst Kristen Kluska maintained PTC Therapeutics with an Overweight rating and raised the price target from $112 to $120.</li>
<li>Wells Fargo analyst Tiago Fauth maintained the stock with an Overweight rating and raised the price target from $74 to $78.</li>
<li>Barclays analyst Gena Wang maintained PTC Therapeutics with an Equal-Weight rating and raised the price target from $42 to $46.</li>
</ul>
Considering buying PTCT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-1024x586.png" alt="" class="wp-image-1005461" style="width:526px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29112141/image-458.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46679452/boeing-procter-gamble-and-3-stocks-to-watch-heading-into-tuesday">Boeing, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

PTCT

These Analysts Increase Their Forecasts On PTC Therapeutics

B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Buy and raises the price target from $68 to $84.

B of A Securities Maintains Buy on PTC Therapeutics, Raises Price Target to $84

Press Releases

Liberty Broadband Corporation Announces First Quarter Earnings Release and Conference Call

Contracts

GCI selects Ericsson to deploy and operate new 5G Core network

Liberty Broadband Reports First Quarter 2025 Financial Results

Liberty Broadband Provides Update Regarding Pending Acquisition by Charter

Liberty Broadband Corporation Declares Quarterly Cash Dividend on Series A Cumulative Redeemable Preferred Stock and Appoints Derek Chang to Board of Directors

Liberty Broadband Corporation Announces GCI Liberty Investor Conference Call

Liberty Broadband Corporation Announces Record Date and Distribution Date for Spin-Off of GCI Liberty, Inc.

Liberty Broadband Corporation Announces When-Issued Trading, Ex-Dividend Date and Trading Symbol Information in Connection with Upcoming Spin-Off of GCI Liberty, Inc.

Comments

Liberty Broadband

Actualités

Dernières nouvelles pour Liberty Broadband (NASDAQ:LBRDK) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL